ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Apigenin exhibits memory enhancing activity through the restoration of oxido-endocrine balance and upregulation of BDNF/ERK/CREB signalling pathways in stressed mice.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Apigenin mitigates oxidative stress, neuroinflammation, and cognitive impairment but enhances learning and memory in aluminum chloride-induced neurotoxicity in rats.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stress is linked to oxidative imbalance, neuroendocrine system malfunction, and cognitive dysfunction. It is a recognized cause of neuropsychiatric diseases. Natural flavonoid apigenin (API) has neuroprotective and antidepressant properties, but little is known about its potential in restoring memory function under stress-related circumstances. This study investigated the potentials of API administration in abrogating chronic unpredictable mild stress (CUMS)-induced cognitive impairment, including exploring its probable underlying mechanisms in mice. Male mice (n = 10) were treated with API (12.5-25 mg/kg, intraperitoneally) 30 min before exposure to CUMS daily for 14 days. Memory function (Y-maze and novel object recognition test (NOR)) was assessed. Concentrations of malondialdehyde (MDA), reduced glutathione (GSH), superoxide dismutase (SOD), were estimated using a spectrophotometer. Corticosterone levels were assessed using an enzyme-linked immunosorbent assay (ELISA). Expressions of brain derived neurotrophic factor (BDNF), phosphorylated extracellular signal-regulated kinase (ERK), and cAMP response element-binding protein (CREB) were assessed using immunohistochemistry. In addition to elevating serum corticosterone and MDA levels, CUMS caused cognitive impairment in mice and decreased GSH, SOD, BDNF, ERK and CREB levels in the prefrontal cortex (PFC) and hippocampus. Administering API restored cognitive function, decreased serum corticosterone and MDA levels, as well as elevated GSH, SOD, BDNF, ERK and CREB levels in the mice brain. The restoration of oxidative, neuroendocrine balance, including upregulating BDNF, CREB, and pERK levels in the brain, all contributed to the neuroprotective effects of API. This suggests that, as shown by the stress paradigm, API may be a promising therapeutic agent for cognitive deficits.
Indexed as
Identifiers
39873717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.